Post Market Clinical Follow-Up of Acetabular Titan-Augment Structan®

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02019433

Enrollment

Registered

2013-12-24

Start date

2012-07-31

Completion date

2014-12-31

Last updated

2017-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Total Hip Arthroplasty Revision

Keywords

THA, augment, revision, pelvis

Brief summary

Implant Survival as well as clinical and radiological Follow-Up of acetabular Titan-Augment Structan®

Interventions

DEVICEStructan®

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Minimum age 18 years * Indication for cementless hip arthroplasty with acetabular defects that need Allograft or titanium augment * Patient consent for study participation * Physical and mental willingness to participate in the follow-ups

Exclusion criteria

* Patient not available for follow-up * Increased anesthetics risks for the patient according to the American Society of Anesthesiology: ASA IV * Tumor * Alcohol- or Drug abuse * Permanent cortisone therapy * Clinically relevant infection * (Planned) pregnancy

Design outcomes

Primary

Measure	Time frame	Description
Implant Survival Rates	12 months	Implant survival is analysed at follow-up examinations at 3 and 12 months

Secondary

Measure	Time frame	Description
Pain	3 and 12 months	Visual Analogue Scale (VAS)
Osteolysis	3 and 12 months	Radiographic Outcome
Clinical Outcome	3 and 12 months	Harris Hip Score
Implant Position	3 and 12 months	Radiographic Outcome
Migration of Structan®	3 and 12 months	Radiographic Outcome
Ossifications	3 and 12 months	Radiographic Outcome

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026